% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • chevelle_69 Apr 20, 2013 1:31 PM Flag

    cHTS Competition

    April 19,2013

    Boston, Mass. - Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Screener 11, a single-platform screening data analysis system with built-in business logic for standardizing and automating screening workflows. The new Genedata Screener now supports compound combination screens to analyze compound synergy effects as well as high throughput flow cytometry including cell sub-population analysis. Integrating with any plate-based instrument, Genedata Screener supports High, Medium and Low Throughput Screens, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies. Now, it also can be used in the cloud to enable pharma-CRO collaboration on the same analysis platform. Genedata Screener 11 will be demonstrated at the Bio-IT World Conference & Expo (World Trade Center; Booth #228; April 9-11).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • chevelle_69 Apr 20, 2013 1:36 PM Flag

      Cloud feature to be the end of the Z's cHTS program? Thoughts?

      Hopefully something will come from the work already done with Novartis. Let's go Z944 and Z160!

      • 1 Reply to chevelle_69
      • chevy69: This is from GTO 68 and 69 always been a Tin Indian guy. LOL
        There a numerous competitors and have been for a long time. Without the data base there is really no completion for the molecules they are screening. There will be many more screening programs coming as well as many more ICB programs. This field is the way of the future and there is plenty of room for a large number of players. The good part is first on the scene should be the top dog, for a particular ailment, if the molecules work . And ZLCS and their partners are first on the dance floor for the ailments they are targeting in many cases.
        Jim Long and calm

        Sentiment: Strong Buy